Application of Shakubatrivalsartan in 5 cases of pediatric dilated cardiomyopathy: case report and literature review
10.3760/cma.j.cn101070-20200729-01263
- VernacularTitle:沙库巴曲缬沙坦在5例儿童扩张型心肌病中的应用并文献复习
- Author:
Ying′en CHEN
1
;
Jianhua LI
;
Hao LIANG
;
Yan LI
;
Caiyan BAI
;
Fei LIN
;
Guoan ZHAO
;
Zhigang CHEN
Author Information
1. 新乡医学院第一附属医院心血管内科，新乡医学院心脏病诊疗中心，河南省心血管损伤与修复国际联合实验室，河南 卫辉 453100
- Keywords:
Shakubatrivalsartan;
Dilated cardiomyopathy;
Heart failure;
Child
- From:
Chinese Journal of Applied Clinical Pediatrics
2021;36(24):1900-1902
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety and therapeutic effect of Shakubatrivalsartan in the treatment of pediatric dilated cardiomyopathy.Methods:Clinical information, treatment and prognosis of 5 cases with dilated cardiomyopathy in the First Affiliated Hospital of Xinxiang Medical University from June 2018 to December 2020 were retrospectively analyzed, and relevant literatures were reviewed.Results:A total of 5 cases of children with dilated cardiomyopathy were analyzed, including 3 males and 2 females with age of 12-17 years.Their median left ventricular ejection fraction (LVEF), left ventricular end diastolic dimension (LVDd), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were 37% (20%-41%), 61 mm (59-67 mm), and 13 250 ng/L (12 310-21 823 ng/L), respectively.The median conventional treatment time was 5 months (1-12 months), in which, the condition of heart failure gradually progressed, and the median LVEF, LVDd and NT-proBNP levels were reduced to 33% (19%-37%), 61 mm (60-74 mm), 13 144 ng/L (8 086-15 137 ng/L). After less than 3 months of follow-up following conventional treatment plus Shakubatrivalsartan, NT-proBNP level significantly decreased in 5 cases.Besides, 4 cases had improved cardiac function, and the other one′s improvement was not obvious.The blood pressure of 5 cases decreased at varying degrees after medication of Shakubatrivalsartan, which should be closely monitored during drug titration.No adverse reactions were reported.Conclusions:Shakubatrivalsartan for the treatment of pediatric dilated cardiomyopathy is safe and effective, which can alleviate or reverse the process of myocardial remodeling and improve cardiac ejection fraction, thus improving the prognosis.
